Prognostic implications of genetic variants in advanced non-small cell lung cancer: a genome-wide association study (Q28943366)

14 March 2017

title

Prognostic implications of genetic variants in advanced non-small cell lung cancer: a genome-wide association study (English)

1 reference

genome-wide association study

14 March 2017

main subject

0 references

1 reference

Youngjoo Lee

1

1 reference

14 March 2017

Kyong-Ah Yoon

2

1 reference

14 March 2017

Jungnam Joo

3

1 reference

14 March 2017

Donghoon Lee

4

1 reference

14 March 2017

Kieun Bae

5

1 reference

14 March 2017

Ji-Youn Han

6

1 reference

14 March 2017

Jin Soo Lee

7

1 reference

14 March 2017

language of work or name

English

0 references

publication date

1 February 2013

1 reference

14 March 2017

1 reference

14 March 2017

volume

34

1 reference

14 March 2017

issue

2

1 reference

14 March 2017

page(s)

307–313

1 reference

describes a project that uses

14 March 2017

genome-wide association study

1 reference

based on heuristic

inferred from title

cites work

Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer.

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS356

XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS356

Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS356

Common genetic variants in cell cycle pathway are associated with survival in stage III-IV non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS356

Genome-wide association study on overall survival of advanced non-small cell lung cancer patients treated with carboplatin and paclitaxel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS356

Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS356

Genome-wide association study of prognosis in advanced non-small cell lung cancer patients receiving platinum-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS356

A genome-wide association study reveals susceptibility variants for non-small cell lung cancer in the Korean population

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS356

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS356

PLINK: a tool set for whole-genome association and population-based linkage analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS356

Haploview: analysis and visualization of LD and haplotype maps

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS356

Randomized phase 2 study of irinotecan plus cisplatin versus gemcitabine plus vinorelbine as first-line chemotherapy with second-line crossover in patients with advanced nonsmall cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS356

A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS356

Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS356

Phase II study of weekly irinotecan plus capecitabine for chemotherapy-naive patients with advanced nonsmall cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS356

First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS356

Common genetic variability in ESR1 and EGF in relation to endometrial cancer risk and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS356

Pathway-based evaluation of 380 candidate genes and lung cancer susceptibility suggests the importance of the cell cycle pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS356

EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS356

Crim1KST264/KST264 mice display a disruption of the Crim1 gene resulting in perinatal lethality with defects in multiple organ systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS356

A genome-wide shRNA screen identifies GAS1 as a novel melanoma metastasis suppressor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS356

Genome-wide association study of pancreatic cancer in Japanese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS356

DNA methylation suppresses expression of the urea cycle enzyme carbamoyl phosphate synthetase 1 (CPS1) in human hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS356

FGF-20 and DKK1 are transcriptional targets of beta-catenin and FGF-20 is implicated in cancer and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS356

Integrative genomic profiling of human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS356

ETV6-NCOA2: a novel fusion gene in acute leukemia associated with coexpression of T-lymphoid and myeloid markers and frequent NOTCH1 mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS356

Genetic polymorphisms in fatty acid metabolism genes and colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS356

ESR1 and EGF genetic variation in relation to breast cancer risk and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS356

Epidermal growth factor genetic variation, breast cancer risk, and waiting time to onset of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS356

Genetic susceptibility of epidermal growth factor +61A>G and transforming growth factor beta1 -509C>T gene polymorphisms with gallbladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS356

The 61 A/G EGF polymorphism is functional but is neither a prognostic marker nor a risk factor for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS356

Exome sequencing and subsequent association studies identify five amino acid-altering variants influencing human height

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS356

A gene expression signature predicts survival of patients with stage I non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS356

Genetic variation in the DNA repair genes is predictive of outcome in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS356